PROMPERÚ
21.4.2022 23:23:12 CEST | Business Wire | Press release
From April 5 to 7, Peru was represented in Berlin at the latest edition of Fruit Logistica 2022, the world's leading fresh fruit and vegetable fair, reports the Commission for the Promotion of Peru for Exports and Tourism (PROMPERÚ).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220416005003/en/
“This time around, Peru's business objective at Fruit Logistica will be to achieve 200 million USD in prospective business for the next 12 months and to generate 6,000 business contacts with the Peruvian delegation, in addition to consolidating a diversified and quality exportable supply,” stated the executive president of PROMPERÚ, Amora Carbajal.
“The sustainability of the Peruvian exportable supply will be a differentiating element at the fair. This is a focus that has been developing within our society and within the business models of Peruvian agro-export companies, improving their competitiveness and reducing environmental impacts through responsible water management, efficient carbon footprint management and fair trade strategies,” said the head of PROMPERÚ.
Fruit Logistica 2022 made it possible to consolidate the position of the Super Food Peru, Pisco, Spirit of Peru and Cafés del Perú brands. The commercial promotion campaign included activations and sampling of exotic fruits and specialty coffees in the national pavilion, in addition to pisco tastings, and typical regional dances.
The delegation led by PROMPERÚ was made up of the Ministry of Agriculture and Irrigation (MIDAGRI), Sierra and Selva Exportadora, Agro Ideas, the Embassy of Peru in Germany, directors of unions and the Association of Agricultural Producer Unions of Peru (AGAP).
Exports
Peruvian food sector exports to the European Union in 2021 reached 3,432 billion USD, growing by more than 13%. The main exports include fresh and dried avocados (604 million USD / +32.3%), unroasted coffee (422 million USD / +23.9%), fresh blueberries (360 million USD / +7.0%), fresh grapes (306 million USD / +28.3%), fresh mangoes (175 million USD / +0.7%), among other products.
In addition, foreign sales of fruit and vegetables amounted to 2,103 billion USD in this same period, with a growth of more than 17%, due to the notable performance of the Netherlands (1,132 billion USD / +19.6%), the United Kingdom (346 million USD / +9.4%), Spain (324 million USD / +22.5%) and Germany (56 million USD / +24.5%). These markets make up 95% of the value exported to the European Union.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220416005003/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 09:31:00 CEST | Press release
Peyman Kargar appointed Director and Chief Executive Officer of TVS Motor Company, effective January 27, 2027 K. N. Radhakrishnan to continue as Director and Chief Executive Officer until then and subsequently will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027 Appointment supports TVS Motor Company's next phase of growth and innovation TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a
Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 21:27:00 CEST | Press release
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom